Navigation Links
TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Date:6/23/2008

LA JOLLA, Calif., June 23 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Dr. Neil Kurtz, President and Chief Executive Officer, will present data obtained from the Phase IIb study that evaluated the safety, tolerability and efficacy of three doses of tezampanel given subcutaneously for treatment of acute migraine at the 50th Annual Scientific Meeting of the American Headache Society in Boston on Saturday, June 28th at 2:00pm, Eastern.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

Company Contact: Media Contact:

Paul Schneider David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x125 212-845-4271

pschneider@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda C
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
2. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
3. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
4. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
5. TorreyPines Therapeutics Reports Third Quarter 2007 Results
6. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
8. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
9. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
10. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
11. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Latin ... the market in Latin America with analysis and forecast ... in 2013, and is expected to reach $2,366.8 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
(Date:10/19/2014)... Asian Automatic patient billing report defines and segments the ... The Automatic patient billing market in Asia is estimated ... a developing CAGR of 7.2% from 2013 to 2018. ... patient billing market, to get an idea of the ... the segmentation of this market in the same region, ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... Israel, April 28 ITGI Medical, Ltd.,(TASE: ITGI) ... of heterologous tissue covered stents, announced that the ... (Humanitarian Use Device),designation to Over and Under(R) and ... dissections of native coronary arteries and,Saphenous Vein Grafts. ...
... Mich., April 28 The following news advisory is ... Business Meeting - During the meeting an important development ... MichBio, Michigan,s trade association for the bioscience industry When: ... Reception , 6:30 p.m. Dinner , 7:00 p.m. Meeting ...
... also Initiates the Phase 2b ASTUTE Clinical Trial for ... Inc., a privately held biopharmaceutical company, announced that data ... treatment of patients with low-grade hepatic encephalopathy was presented ... European Association for the Study of Liver Disease (EASL) ...
Cached Biology Technology:Key Industry-Relevant Development to be Announced at MichBio's 2009 Annual Meeting on May 6 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 3
(Date:10/15/2014)... in female mice to an enzyme activated by the ... resistant to respiratory infections than males. Now, an international ... bacterial pneumonia in female mice is linked to the ... that this enzyme is ultimately activated by the release ... lead by Professor Lester Kobzik at the Harvard University ...
(Date:10/14/2014)... discriminating thieves, prostate cancer tumors scavenge and hoard copper ... such avarice may be a fatal weakness. , ... kill prostate cancer cells by delivering a trove of ... diseased cells brimming with the mineral, leaving non-cancer cells ... already commercially available for other uses, could soon be ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... climate change projected this century for Oregon,s Upper ... supplies, buildings, transportation systems, human health, forests, and ... by the University of Oregon,s Climate Leadership Initiative ... Policy. The authors say that extensive efforts ...
... toward renewable energy, questions persist about the Earth,s climate. ... natural variations in climate or other causes responsible? A ... such questions during a presentation at the University of Houston ... open to the public. Warren M. Washington, ...
... of the Flint Hills may no longer provide a ... birds, according to research by a Kansas State University ... three bird species common to the Flint Hills region ... in the face of extensive land-management practices like annual ...
Cached Biology News:Eugene-Springfield face Upper Willamette climate threats 2Eugene-Springfield face Upper Willamette climate threats 3Eugene-Springfield face Upper Willamette climate threats 4Prominent climate researcher to speak at UH on global warming March 5 2Birds in Flint Hills of Kansas, Oklahoma face population decline despite large habitat 2Birds in Flint Hills of Kansas, Oklahoma face population decline despite large habitat 3
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
Cell Culture Flask, 75 cm, treated polystyrene...
Cell Culture Flask, 75 cm, nontreated polystyrene...
... virtually every research laboratory, the revolutionary Luminex ... accurately, inexpensively and in real time enhancing ... analysis system includes the Luminex 100, the ... xMAP technology which enables you to simultaneously ...
Biology Products: